) recently presented positive data from a preclinical study on
NKTR-214. NKTR-214 targets the interleukin-2 (IL-2) receptor
complex and is being developed or the treatment of multiple
Results from the preclinical study revealed that NKTR-214
improved pharmacokinetics and also enhanced tumor penetration
that permits a ten-fold reduction in overall dosing.
We note that this is not the only oncology candidate at
Nektar. The company's lead oncology candidate is NKTR-102
(etirinotecan pegol), being developed for the treatment of
patients suffering from metastatic breast cancer. Nektar is
currently evaluating the candidate in the phase III BEACON study
(BrEAst Cancer Outcomes with NKTR-102).
Nektar is expected to enrol around 840 women with metastatic
breast cancer by the end of this year. Data is expected by the
end of 2014. In Nov 2012, NKTR-102 was designated as a Fast Track
development program by the US Food and Drug Administration
NKTR-102 is also being developed for the treatment of ovarian
cancer. During the fourth quarter of 2012 the company completed a
phase II study on the candidate. Results from the study showed
that NKTR-102 has significant activity in platinum-resistant and
refractory ovarian cancer.
Moreover, in Aug 2012, Nektar commenced a phase II
investigator-initiated clinical trial on NKTR-102 in patients
) Avastin (bevacizumab)-resistant high-grade glioma (a type of
tumor). The study is being conducted at the Stanford Cancer
In Feb 2013, the company initiated another phase II
investigator-initiated study on the candidate in patients
suffering from metastatic and recurrent non-small cell lung
cancer. The study is being conducted at the Abramson Cancer
Center of the University of Pennsylvania.
We note that the oncology market is extremely competitive with
the presence of companies like Roche and
Nektar, a biopharma company, currently carries a Zacks Rank #3
NEKTAR THERAP (NKTR): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Get Free Report
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.